 |
|
The Effects of Immunosuppressive and Anti-inflammatory Medications on Fertility, Pregnancy, and Lactation
Namieta M. Janssen, MD;
Marcia S. Genta, MD
Arch Intern Med. 2000;160:610-619.
Many rheumatic diseases affect women of childbearing age, and the medications used to treat these diseases may affect conception, pregnancy, fetal development, and lactation. Physicians who care for these women need to be aware of the potential adverse effects of these medications, and which medications can be used safely prior to conception and during pregnancy and lactation. Although reviews of individual classes of medications are available, there is no practical and comprehensive review that summarizes all of this information, and includes anticoagulant drugs and 2 recently approved drugs for rheumatoid arthritis. Women who take cytotoxic drugs should be informed of the risks of impaired fertility and congenital malformations, and must use effective methods of contraception. During pregnancy, nonsteroidal anti-inflammatory agents may be used until the last 6 weeks, and low to moderate doses of corticosteroids are safe throughout pregnancy. Among the disease-modifying agents, sulfasalazine and hydroxychloroquine treatment may be maintained. Cytotoxic drugs may be used after the first trimester to treat life-threatening disease. During lactation, prednisone, sulfasalazine, and hydroxychloroquine may be used cautiously. Women using heparin for treatment of antiphospholipid antibody syndrome should take measures to prevent bone loss. Men taking methotrexate, sulfasalazine, cyclosporine, azathioprine, or leflunomide should be apprised of the possibilities of infertility and teratogenicity.
From the Section of Immunology, Allergy, and Rheumatology, Department of Medicine, Baylor College of Medicine, Houston, Tex.
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2000;160(5):718-719.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants
Biggioggero et al.
Lupus 2007;16:651-656.
ABSTRACT
Eczema in pregnancy
Weatherhead et al.
BMJ 2007;335:152-154.
FULL TEXT
Revisiting the Toxicity of Low-Dose Glucocorticoids: Risks and Fears
DA SILVA et al.
Ann. N. Y. Acad. Sci. 2006;1069:275-288.
ABSTRACT
| FULL TEXT
Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data
Da Silva et al.
Ann Rheum Dis 2006;65:285-293.
ABSTRACT
| FULL TEXT
A case of successful pregnancy in a woman with systemic sclerosis treated with cyclosporin
Basso et al.
Rheumatology (Oxford) 2004;43:1310-1311.
FULL TEXT
Pregnancy in a rheumatoid arthritis patient on infliximab and methotrexate
Kinder et al.
Rheumatology (Oxford) 2004;43:1195-1196.
FULL TEXT
Therapeutic Strategies for Rheumatoid Arthritis
O'Dell
NEJM 2004;350:2591-2602.
FULL TEXT
Chloroquine gestational use in systemic lupus erythematosus: assessing the risk of child ototoxicity by pure tone audiometry
Borba et al.
Lupus 2004;13:223-227.
ABSTRACT
Anovulation in the prevention of cytotoxic-induced follicular attrition and ovarian failure
Letterie
Hum Reprod 2004;19:831-837.
ABSTRACT
| FULL TEXT
Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study
Li et al.
BMJ 2003;327:368.
ABSTRACT
| FULL TEXT
Interactions of Human Organic Anion Transporters and Human Organic Cation Transporters with Nonsteroidal Anti-Inflammatory Drugs
Khamdang et al.
J. Pharmacol. Exp. Ther. 2002;303:534-539.
ABSTRACT
| FULL TEXT
Antirheumatic drugs in pregnancy
Harris
Lupus 2002;11:683-689.
|
